Why the study?
Does restarting warfarin therapy affect the risk of recurrence or thromboembolization in patients with a recent warfarin-associated intracerebral hemorrhage?
Does restarting warfarin therapy affect the risk of recurrence or thromboembolization in patients with a recent warfarin-associated intracerebral hemorrhage?
Restarting warfarin after a warfarin-associated intracerebral hemorrhage presents a clinical dilemma balancing low recurrence risk against thromboembolic risk if withheld.
Supports cautious resumption of warfarin after ICH in selected patients; leaves open the need for RCTs to guide practice.
Restarting warfarin therapy in patients with a recent WAICH is associated with a low risk of recurrence, but patients are subjected to known, substantial risks of warfarin use. Withholding warfarin therapy is associated with a risk of thromboembolization.
No takes yet. Share an insight, caveat, or question.
Claassen et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: